MBX Biosciences Statistics
Total Valuation
MBX Biosciences has a market cap or net worth of $1.38 billion. The enterprise value is $1.01 billion.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MBX Biosciences has 47.57 million shares outstanding. The number of shares has increased by 243.01% in one year.
| Current Share Class | 47.57M |
| Shares Outstanding | 47.57M |
| Shares Change (YoY) | +243.01% |
| Shares Change (QoQ) | +31.19% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 67.91% |
| Float | 29.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.62, with a Debt / Equity ratio of 0.00.
| Current Ratio | 24.62 |
| Quick Ratio | 24.25 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.76% and return on invested capital (ROIC) is -19.53%.
| Return on Equity (ROE) | -27.76% |
| Return on Assets (ROA) | -18.75% |
| Return on Invested Capital (ROIC) | -19.53% |
| Return on Capital Employed (ROCE) | -26.53% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.38M |
| Employee Count | 63 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +216.69% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +216.69% |
| 50-Day Moving Average | 31.72 |
| 200-Day Moving Average | 24.98 |
| Relative Strength Index (RSI) | 38.77 |
| Average Volume (20 Days) | 477,842 |
Short Selling Information
The latest short interest is 3.79 million, so 7.96% of the outstanding shares have been sold short.
| Short Interest | 3.79M |
| Short Previous Month | 3.59M |
| Short % of Shares Out | 7.96% |
| Short % of Float | 13.04% |
| Short Ratio (days to cover) | 7.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -98.06M |
| Pretax Income | -86.97M |
| Net Income | -86.97M |
| EBITDA | -97.81M |
| EBIT | -98.06M |
| Earnings Per Share (EPS) | -$2.38 |
Full Income StatementBalance Sheet
The company has $373.71 million in cash and $596,000 in debt, giving a net cash position of $373.11 million or $7.84 per share.
| Cash & Cash Equivalents | 373.71M |
| Total Debt | 596,000 |
| Net Cash | 373.11M |
| Net Cash Per Share | $7.84 |
| Equity (Book Value) | 369.22M |
| Book Value Per Share | 8.22 |
| Working Capital | 366.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$79.95 million and capital expenditures -$1.93 million, giving a free cash flow of -$81.88 million.
| Operating Cash Flow | -79.95M |
| Capital Expenditures | -1.93M |
| Depreciation & Amortization | 248,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -81.88M |
| FCF Per Share | -$1.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |